A Third REMS Advantage? Allergan Says REMS for Botox Requires Off-Label...
Allergan sued the FDA earlier this month, claiming that the FDA’s prohibition of off-label promotion violates Allergan’s First Amendment rights by preventing Allergan from communicating about BOTOX’s...
View ArticleMonday Biotech Deal Review: February 14, 2011
Welcome to the Monday Biotech Deal Review for February 14, 2011. Aside from the usual assortment of corporate and regulatory announcements over the week, the highlights include SemBioSys’ proposed $4M...
View Article
More Pages to Explore .....